1. Introduction {#s0005}
===============

Cancer is one of the leading causes of morbidity and mortality globally. The World Health Organization (WHO) estimated that cancer led to 9.6 million deaths worldwide in 2018, indicating that 1 in 6 deaths was due to cancer ([@b0235]). According to the International Agency for Research on Cancer, the number of newly diagnosed cases of cancer is expected to increase by 70% over the next two decades ([@b0200]). In Saudi Arabia, the number of newly diagnosed cancer cases in 2014 was 15,807. Among them, 76% were Saudi citizens, and women represented 52.8% of the cases ([@b0025]).

Despite the recent advances in molecular biology and immunology of cancer, chemotherapy remains the most commonly used therapeutic modality ([@b0055]). Several studies have proven the efficacy of chemotherapy in improving the survival rates among patients with different types of cancer ([@b0155]). However, chemotherapeutic agents cause a broad spectrum of adverse drug reactions that are both physical and psychological in nature ([@b0085], [@b0170]). The antineoplastics' side effects range from mild, such as nausea and vomiting ([@b0110], [@b0105]), and hair loss ([@b0040]), to severe adverse drug reactions, such as cardiac ([@b0215]), vascular ([@b0020]), neurologic ([@b0060]), cognitive ([@b0065]), renal ([@b0095]), hepatic ([@b0005]), and gastrointestinal disorders ([@b0075]). These side effects can lead to treatment interruption or discontinuation ([@b0030]). Therefore, the assessment of antineoplastic drugs' side effects is essential not only to improve patient quality of life, but also to maintain a high quality of patient care ([@b0135], [@b0140], [@b0195], [@b0120], [@b0230], [@b0190], [@b0010]).

Several tools have been developed and used to assess patients' perception of chemotherapy side effects. They include the Visual Analogue Scale (VAS) ([@b0090]), and Time Trade-off (TTO) ([@b0145]), which were used to identify nausea and vomiting as the most bothersome side effects reported by ovarian cancer patients ([@b0205]). Similar conclusions were reached among this group of patients using the VAS and Memorial Symptom Assessment Scale (MSAS) ([@b0210]). The negative impact of nausea and vomiting on cancer patients' quality of life has also been documented using different patient reported measures such as the Morrow Assessment of Nausea and Emesis (MANE) ([@b0160]). In another study that assessed the chemotherapy side effects using a 5-point Likert-type scale, hair loss, nausea and vomiting, and changes in taste and smell perception were identified as the most frequently reported aggravating side effects of chemotherapy ([@b0120]). In general, questionnaires using a Likert-type scale are the most frequently used for the evaluation of antineoplastics\' side effects ([@b0130], [@b0180]). The M.D. Anderson Symptom Inventory (MDASI) is one of these widely used tools for the severity assessment of 13 different side effects among cancer patients undergoing chemotherapy ([@b0150], [@b0045]). It is mainly focused on the extent to which antineoplastics' side effects interfere with patients' activities of daily living using an 11-point rating scale from 0 to 10, where zero indicates the absence of a side effect and 10 means that the side effect is as bad as the patient can imagine ([@b0175]). It was the intention of the authors of MDASI to generate an antineoplastics' side effects assessment tool that is easy to translate into other languages ([@b0050]). In fact, the MDASI has been translated into different languages including the Arabic language ([@b0165]). Although it remains the only available Arabic-language tool for the assessment of antineoplastics\' side effects, its validity among different Arabic-speaking populations other than the Moroccan cancer patient population in which the MDASI was validated in was not examined ([@b0165]). Furthermore, the MDASI only covers 13 cancer-related symptoms over the last 24 hours, and includes six items that assess the interference of these symptoms with the patients' activities of daily living. Another scale that was developed almost 15 years ago is the Functional Assessment of Cancer Therapy General (FACT-G). The scale consists of 33 items assessing the impact of different antineoplastics' side effects on the patient physical, emotional, social/family, and functional well-being. Also, the FACT-G assesses the patient-physician relationship. However, the FACT-G scale does not list different antineoplastics' side effects, but rather focuses on the impact of these side effects on the patient well-being ([@b0035]). Therefore, it was complemented with another scale to rank the top most bothersome antineoplastics' side effects among cancer and non-cancer patients ([@b0120]). There are also other scales that showed both high validity and reliability in assessing antineoplastics' side effects among cancer patients. However, these scales are specific to certain types of cancer ([@b0210], [@b0115], [@b0015]). The Memorial Symptom Assessment Scale (MSAS) is one of these scales that was validated among ovarian cancer patients and assesses 27 health states associated with chemotherapy ([@b0210]). Other scales focus on few side effects such as the Marrow Assessment of Nausea and Emesis (MANE) which is a 17-item scale that assesses the frequency, severity, and duration of pre- and post-chemotherapy induced nausea and vomiting ([@b0160]). The Brief Fatigue Inventory (BFI) is another scale that assesses the severity of fatigue among cancer patients ([@b0150]). Unfortunately, a comprehensive, concise, and general scale that covers the most frequently reported antineoplastics' side effects among cancer patients undergoing chemotherapy in general and assesses the severity and impact of these side effects on cancer patients' lives is not yet available. Therefore, the availability of such scales in Arabic and other languages is important to address the needs of underserved patient populations and eventually improve the quality of care ([@b0115], [@b0015], [@b0125]). The objective of the present study was to develop a concise, general, and comprehensive patient-reported antineoplastics' side effects questionnaire among Arabic-speaking cancer patient population. The expectation was that an accurate evaluation of cancer patients' perceptions of antineoplastics' side effects and their impact on patient activities of daily living would improve the quality of care provided to this patient population.

2. Methods {#s0010}
==========

2.1. Study design and setting {#s0015}
-----------------------------

The present investigation was designed as a cross-sectional, observational, single-center study. It was conducted in the oncology clinics at a university-affiliated tertiary care hospital in Riyadh, Saudi Arabia. All enrolled patients had a confirmed diagnosis of cancer regardless of cancer type and grade, were 18 years of age or older, completed at least four weeks of chemotherapy, and were cognitively able to talk. Exclusion criteria were an age less than 18 years, length of chemotherapy shorter than 4 weeks, cognitive impairment, and inability to speak due to deafness, mutism, aphasia, or other health reasons.

2.2. Development of the antineoplastic side effects scale (ASES) {#s0020}
----------------------------------------------------------------

An extensive review of the relevant literature published between 1980 and 2018 was conducted to identify the most commonly reported side effects of antineoplastic drugs. ([@b0070]) After a thorough review of all commonly reported antineoplastics' side effects in the literature, the authors decided to include the 40 most commonly reported side effects to be as comprehensive as possible. These include emotional and cognitive side effects (feeling nervous, feeling sad or depressed, feeling angry, higher tendency to cry, anxiety, fear, confusion, difficulty concentrating, difficulty remembering things or forgetfulness), physical side effects (pain, numbness and tingling in feet or hands, palpitation, shortness of breath, changes in how things smell or taste, painful or increased urination, dizziness, lack of energy or lethargy, disturbed sleep, problems with sexual interest or activity), gastrointestinal side effects (dry mouth, sore mouth or throat, nausea, vomiting, diarrhea, constipation, feeling bloated, abdominal pain, increased or poor appetite, difficulty swallowing, weight loss, weight gain, excessive thirst), and cutaneous side effects (itching, hair loss, excessive hair growth, changes in skin color, skin rash, dry skin, acne, easy bruising). Also, the authors felt the need to allow patients report other side effects that are not listed in the newly developed scale should they have any. The new scale was named the Antineoplastic Side Effects Scale (ASES) and was suited for self-administration. The ASES consists of three subscales. The first subscale is descriptive and assesses the frequency of the side effects (every day, 4--6 days per week, 2--4 days per week, once a week and less than once a week). The second subscale evaluates the severity of the side effects. For each listed side effect, the patient selects a value from 0 to 10, where zero indicates that the side effect does not exist, and 10 indicates that the side effect is as bad as the patient can imagine. The lowest possible score of this subscale is 0, and the highest is 400. The third subscale assesses the extent to which the side effects -- if present -- interfere with the patients' daily activities. This subscale utilizes a 5-point Likert scale, with 1 indicating "not at all," 2 "a little bit," 3 "somewhat", 4 "quite a bit," and 5 "very much." The highest possible score on this subscale is 200.

The first draft of the questionnaire was reviewed by two clinical pharmacists and one oncologist and sent back to all coauthors for their evaluation and comments. After minor modifications, the draft was sent to an Arabic linguist for lingual and semantic review and comments. All remarks and comments were addressed, and the final version of ASES was approved. The face and content validity of the ASES was examined by three clinical pharmacists, an oncologist, and a psychiatrist. No outstanding issues were found.

2.3. Data collection {#s0025}
--------------------

Patients were recruited from the oncology clinics at a university-affiliated hospital in the city of Riyadh, Saudi Arabia. An informed consent form explaining the purpose of the study and the patients' rights, including their right to withdraw from the study at any time, was presented to all participants. The study was approved by the hospital's Institutional Review Board (IRB).

The patients were interviewed by four pharmacists. The collected information included sociodemographic, and cancer type and grade characteristics which were retrieved from the patient electronic health records. Comorbidities were retrieved from the patient electronic health records and verified using the Self-Administered Comorbidity Questionnaire (SCQ) to assess the burden of illness ([@b0185]). The frequency and severity of other potential side effects that were not listed in the ASES were also assessed.

2.4. Statistical analysis {#s0030}
-------------------------

The data were analyzed using the SAS statistical software (version 9.2, SAS Institute Inc., Cary, NC, USA). Descriptive statistics were conducted using Student's *t*-test and Chi-square test, as appropriate. The reliability of the questionnaire was examined using Cronbach's alpha method ([@b0220]). The Kaiser-Meyer-Olkin test (KMO) was used to assess sampling adequacy ([@b0100]). To examine the construct validity of the Antineoplastic Side Effects Scale (ASES), principal component analysis with varimax rotation was performed. Pearson's correlation coefficient was used to examine the association between the scores of the ASES subscales and the different patient medical and sociodemographic characteristics. Statistical significance was defined at α \< 0.05.

3. Results {#s0035}
==========

3.1. Patients {#s0040}
-------------

The inclusion criteria were met by 98 patients, 78 (79.6%) of them consented to participate and were interviewed. The sociodemographic and medical characteristics of the enrolled patients are listed in [Table 1](#t0005){ref-type="table"}. The mean age of the participants was 53.8 (12.5) years, and the majority (58.9%) were between 51 and 65 years of age. Fifty-one patients (65.3%) were female, and 66 (84.6%) were married. There were only 5 smokers, and approximately 42% of the patients were using herbal supplements.Table 1The sociodemographic and medical characteristics of the participants.CharacteristicFrequency (%)*Age (years)*18--252(2.56)26--303(3.85)31--353(3.85)36--406(7.69)41--453(3.85)46--504(5.13)51--5519(24.32)56--6019(24.32)61--658(10.26)66--705(6.41)71--752(2.56)76--804(5.13)  *Gender*Male27(34.62)Female51(65.38)  *Marital status*Single8(10.26)Married66(84.62)Divorced1(1.28)Widowed3(3.85)  *Smoking status*Nonsmoker73(93.59)Smoker5(6.41)  *Use of herbal supplements*No45(57.69)Yes33(42.31)  *Type of cancer*Colorectal cancer19(24.36)Breast cancer24(30.77)Lung cancer3(3.85)Liver cancer1(1.28)Leukemia2(2.56)Lymphoma5(6.41)Uterine cancer1(1.28)Ovarian cancer3(3.85)Cervical cancer1(1.28)Prostate cancer1(1.28)Stomach cancer1(1.28)Pancreatic cancer5(6.41)Thyroid cancer1(1.28)  *Chemotherapy duration*4--6 weeks5(6.41)More than 6 weeks73(93.59)  *Self-Administered Comorbidity Questionnaire (SCQ) score*3--520(25.64)6--837(47.44)9--1116(20.51)\>115(6.41)

The most frequent types of cancer were breast (30.7%) and colorectal (24.3%) cancers ([Table 1](#t0005){ref-type="table"}). Forty-eight patients (61.5%) had poorly differentiated tumors (grade III), and 23 (29.4%) had moderately differentiated tumors (grade II). The vast majority of the patients (93.5%) underwent chemotherapy for more than 6 weeks. Most of the patients were on antimetabolite chemotherapy (17.9%), 16.6% were treated with alkylating agent and antimetabolite agents, 11.5% were given antimicrotubular agents, and 8.9% were receiving both antimicrotubular agents and monoclonal antibodies. The self-administered comorbidity questionnaire indicated that most (74.4%) scored at least 6 points, indicating a significant burden of illness.

3.2. Development and evaluation of the antineoplastic side effects scale {#s0045}
------------------------------------------------------------------------

The complete list of the 40 side effects included in the ASES questionnaire and their frequency in the enrolled group of patients is presented in [Table 2](#t0010){ref-type="table"}. The most frequent side-effects, reported by 50% or more of the patients were lack of energy (lethargy) (73.08%), generalized pain (69.2%), increased or poor appetite (62.8%), disturbed sleep (58.9%), diarrhea (57.6%), hair loss (55.1%), feeling bloated (52.5%), changes in how things smell or taste (51.2%), dry mouth (51.2%), feeling nervous (50%), constipation (50%) and dry skin (50%). The ASES Cronbach's alpha value was 0.91which indicates an acceptable reliability.Table 2The frequency of Antineoplastic Side Effects Scale (ASES) items.Side effectFrequency (%)Feeling nervous39(50.00)Feeling sad or depressed36(46.15)Feeling angry33(42.31)Crying more often18(23.08)Anxiety32(41.03)Fear18(23.08)Confusion16(20.51)Difficulty concentrating24(30.77)Difficulty remembering things30(38.46)Generalized pain54(69.23)Numbness and tingling sensation in feet or hands37(47.44)Palpitation25(32.05)Shortness of breath19(24.36)Changes in how things smell or taste40(51.28)Painful or Increased urination31(39.74)Dizziness34(43.59)Lack of energy57(73.08)Disturbed sleep46(58.97)Problems with sexual interest or activity13(16.67)Dry mouth40(51.28)Sore mouth or throat34(43.59)Nausea36(46.15)Vomiting25(32.05)Diarrhea45(57.69)Constipation39(50.00)Feeling bloated41(52.56)Abdominal pain29(37.18)Increased or poor appetite49(62.82)Difficulty swallowing21(26.92)Weight loss32(41.03)Weight gain25(32.05)Excessive thirst37(47.44)Itching31(39.74)Hair loss43(55.13)Excessive hair growth24(30.77)Changes in skin color30(38.46)Skin rash10(12.82)Dry skin39(50.00)Acne5(6.41)Easily bruising22(28.21)

When the severity subscale of the ASES was considered ([Table 3](#t0015){ref-type="table"}), generalized pain and lack of energy appeared to be the most acutely perceived side effects, with a score of 5.3 (4.0) and 5.3 (3.7), respectively, on a scale ranging from 0 to 10. Other side effects with a high degree of severity included increased or poor appetite (4.8 \[4.0\]), disturbed sleep (4.5 \[4.0\]), hair loss (4.2 \[4.1\]), and changes in how things smell or taste (4.1 \[4.2\]). The least bothersome side effects were acne (0.2 \[1.2\]) and skin rash (0.9 \[2.5\]).Table 3The mean scores of the Antineoplastic Side Effects Scale (ASES) severity subscale.Side effectMean ± SDFeeling nervous3.3 ± 3.7Feeling sad or depressed3.2 ± 3.8Feeling angry2.7 ± 3.6Crying more often1.4 ± 3.0Anxiety2.3 ± 3.4Fear1.6 ± 3.2Confusion1.4 ± 3.1Difficulty concentrating1.6 ± 2.6Difficulty remembering things2.2 ± 3.1Generalized pain5.3 ± 4.0Numbness and tingling sensation in feet or hands2.8 ± 3.4Palpitation1.8 ± 3.0Shortness of breath1.5 ± 3.0Changes in how things smell or taste4.1 ± 4.2Painful or Increased urination2.5 ± 3.4Dizziness2.8 ± 3.7Lack of energy5.3 ± 3.7Disturbed sleep4.5 ± 4.0Problems with sexual interest or activity1.3 ± 3.0Dry mouth3.6 ± 3.9Sore mouth or throat3.0 ± 3.8Nausea3.2 ± 3.9Vomiting2.4 ± 3.9Diarrhea3.8 ± 3.9Constipation3.5 ± 3.8Feeling bloated3.5 ± 3.7Abdominal pain2.6 ± 3.6Increased or poor appetite4.8 ± 4.0Difficulty swallowing1.5 ± 2.7Weight loss2.0 ± 2.6Weight gain1.3 ± 2.2Excessive thirst3.4 ± 3.8Itching2.5 ± 3.5Hair loss4.2 ± 4.1Excessive hair growth1.5 ± 2.6Changes in skin color2.7 ± 3.7Skin rash0.93 ± 2.5Dry skin3.4 ± 3.8Acne0.28 ± 1.2Easily bruising1.7 ± 3.0  Total score114.5 ± 64.6

On the ASES subscale describing the impact of side effects on activities of daily living ([Table 4](#t0020){ref-type="table"}), the highest scores (range from 0 to 5) were reported for the lack of energy (2.2 \[1.7\]), generalized pain (2.0 \[1.8\]), and disturbed sleep (1.7 \[1.7\]). The least consequential side effects were acne (0.1 \[0.6\]), skin rash (0.3 \[1.1\]), confusion (0.4 \[1.0\]), and crying more often (0.4 \[1.0\]).Table 4The mean scores of the Antineoplastic Side Effects Scale (ASES) impact on activities of daily living subscale.Side effectMean ± SDFeeling nervous1.2 ± 1.6Feeling sad or depressed1.1 ± 1.6Feeling angry0.89 ± 1.4Crying more often0.47 ± 1.0Anxiety0.89 ± 1.5Fear0.56 ± 1.3Confusion0.42 ± 1.0Difficulty concentrating0.55 ± 0.99Difficulty remembering things0.7 ± 1.1Generalized pain2.0 ± 1.8Numbness and tingling sensation in feet or hands0.96 ± 1.4Palpitation0.66 ± 1.2Shortness of breath0.56 ± 1.2Changes in how things smell or taste1.2 ± 1.6Painful or Increased urination0.86 ± 1.3Dizziness0.91 ± 1.3Lack of energy2.2 ± 1.7Disturbed sleep1.7 ± 1.7Problems with sexual interest or activity0.65 ± 1.5Dry mouth1.2 ± 1.5Sore mouth or throat1.2 ± 1.6Nausea1.2 ± 1.6Vomiting0.93 ± 1.6Diarrhea1.3 ± 1.6Constipation1.2 ± 1.6Feeling bloated1.2 ± 1.5Abdominal pain0.91 ± 1.5Increased or poor appetite1.5 ± 1.6Difficulty swallowing0.58 ± 1.1Weight loss0.76 ± 1.1Weight gain0.66 ± 1.2Excessive thirst0.97 ± 1.3Itching0.81 ± 1.3Hair loss1.2 ± 1.5Excessive hair growth0.72 ± 1.4Changes in skin color0.85 ± 1.4Skin rash0.36 ± 1.1Dry skin0.93 ± 1.2Acne0.13 ± 0.6Easily bruising0.52 ± 1.0  Total score40.3 ± 27.9

3.3. Principal component analysis {#s0050}
---------------------------------

The Kaiser-Meyer-Olkin test (KMO) indicated that the sample size was adequate to conduct this type of evaluation. From each subscale, three factors were extracted based on the ASES loadings: psycho-somatic side effects, gastro-somatic side effects, and cognitive-somatic side effects. The extracted factors alongside their items with their communality estimates that represent the proportion of each item's variance that can be explained by their assigned factors are shown in [Table 5](#t0025){ref-type="table"}.Table 5Extracted factors from the Antineoplastic Side Effects Scale (ASES).Severity of the side effectFactorsCommunalities (h2)(1)(2)(3)Fear0.780.68Anxiety0.760.64Feeling nervous0.720.69Confusion0.700.64Crying more often0.610.66Feeling sad or depressed0.600.58Feeling angry0.560.50Dry mouth0.530.48Excessive hair growth0.400.21Generalized Pain0.360.32Sore mouth or throat0.340.46Acne0.330.46Excessive thirst0.410.55Weight gain0.080.31Itching0.260.63Nausea0.660.51Lack of energy0.620.63Increased or poor appetite0.610.45Hair loss0.600.42Weight loss0.560.35Diarrhea0.530.35Vomiting0.530.43Difficulty swallowing0.490.55Abdominal pain0.490.32Constipation0.470.27Dizziness0.460.25Feeling bloated0.290.24Skin rash0.320.39Changes in skin color0.400.40Problems with sexual interest or activity0.190.28Easily bruising0.740.64Difficulty concentrating0.590.47Palpitation0.590.47Dry skin0.500.47Changes in how things smell or taste0.490.33Difficulty remembering things0.450.40Disturbed sleep0.420.45Numbness and tingling in feet or hands0.210.08Shortness of breath0.240.45Painful or Increased urination0.260.55

Finally, the Pearson's correlation coefficients that examined the relationship between the severity of side effects and patients' characteristics, and between the impact of side effects on patients' activities of daily living and their characteristics are shown in [Table 6](#t0030){ref-type="table"}. Among all the variables analyzed, only female gender was positively and significantly related to the severity of side effects (*P* \< 0.001). Similarly, the female gender was the only variable that has shown a significant correlation with the perceived impact on activities of daily living ([Table 7](#t0035){ref-type="table"}). In both analyses, no correlation was identified for age, marital status, smoking, use of herbal supplements, and the SCQ score.Table 6The correlation between Antineoplastic Side Effects Scale (ASES) severity subscale's score and participants' sociodemographic and medical characteristics.CharacteristicPearson correlation coefficient (r)*P*-valueAge−0.050.65Female gender0.43\<0.001[\*](#tblfn1){ref-type="table-fn"}Marital status0.180.12Smoking status−0.210.06Use of herbal supplements0.020.88Chemotherapy duration−0.0690.55Self-Administered Comorbidity Questionnaire (SCQ) score0.20.078[^1]Table 7The correlation between Antineoplastic Side Effects Scale (ASES) impact on activities of daily living subscale's score and participants' sociodemographic and medical characteristics.CharacteristicPearson correlation coefficient (r)*P*-valueAge−0.0290.8Gender0.41\<0.001[\*](#tblfn2){ref-type="table-fn"}Marital status0.140.22Smoking status−0.1860.1Use of herbal supplements0.010.92Chemotherapy duration−0.120.3Self-Administered Comorbidity Questionnaire (SCQ) score0.0990.39[^2]

4. Discussion {#s0055}
=============

To the best of our knowledge, the new developed Antineoplastic Side Effects Scale (ASES) represents the most comprehensive tool available in the Arabic language for the evaluation of patient's perception of antineoplastics' side effects among Arabic speaking cancer patients. It is expected that the availability of an Arabic ASES will help improve the quality of care of Arabic speaking cancer patients undergoing chemotherapy. This scale had good internal consistency, with Cronbach's alpha of 0.91, significantly higher than the value of 0.7 required for validation of new instruments ([@b0225]).

It is expected that the use of ASES, which screens for 40 distinct and commonly reported side effects of chemotherapy, will result in a more comprehensive evaluation of the cancer patients' experiences with chemotherapy than the ones offered by shorter questionnaires, such as the MDASI ([@b0070]). Another advantage of ASES stems from the fact that the collected data can be used to prepare patients in advance for commonly reported side effects of chemotherapy and facilitate symptoms management ([@b0080]). Besides the long list of commonly reported antineoplastics' side effects that ASES covers compared to the Arabic version of MDASI ([@b0165]), it is the first antineoplastics' side effects scale that was developed and validated in Arabic by a diverse group of healthcare professionals and researchers.

5. Limitations of the current study {#s0060}
===================================

Although ASES has demonstrated good reliability, some limitations inherent in the present study have to be acknowledged. The study was restricted to a relatively small number of patients under the care of a single oncology center. Examining the validity and reliability of ASES in a larger sample of cancer patients and in different healthcare settings is essential to assess its external validity. Furthermore, the validity of the proposed scale can be further strengthened by evaluating the correlation of its scores with other commonly used antineoplastic side-effects scales such as the MDASI. Moreover, this scale is only available in Arabic since it was validated among Arabic-speaking cancer patients, which limits its usability.

6. Conclusion {#s0065}
=============

The availability of a comprehensive, concise, and general scale in Arabic to explore cancer patients' self-reported antineoplastic agents\' side effects and assess their impact on activities of daily living should help healthcare providers and patients alike to mitigate the negative impact of these therapeutic agents. Also, it will enable healthcare researchers in comparing and contrasting the incidence and severity of antineoplastics\' side effects among Arabic speaking cancer patients and patients from other ethnicities. Future studies should examine the validity and reliability of Arabic, English, and other language versions of ASES among larger and more diverse patient populations.
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